Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.58) by 13...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates PolyPid (NASDAQ:PYPD) with a Buy and maintains $14 price target.
- SEC Filing
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(3.97) per share which missed the analyst consensus estimate of $(3.58) by ...
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on r...
The Company intends to conduct an unblinded interim analysis once a total of approximately 400 patients complete their 30-day f...
Shares of Applied Therapeutics, Inc.
The PIPE syndicate is comprised of new and existing investors, including participation from new U.S. life sciences-focused inve...
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(3.40) per share which beat the analyst consensus estimate of $(4.16) by 18...
